David is a co-founder of Prosonix and has led the Company as CEO since its establishment in 2006, raising more than £22 million from international life sciences investors. Prior to Prosonix, he was General Manager of the C3 Technology Business of Accentus, which he established after joining them in 2002. David has more than 20 years of business development experience concerning cutting-edge technologies in high growth, complex, intellectual property-rich environments, with a prime focus on the pharmaceutical industry. He has also held a number of senior positions in Dow Pharma, Ascot plc, ChiroTech Ltd, and Air Products plc. David holds a BSc in Chemical Engineering.

Andy is a co-founder of Prosonix and, as COO/CFO, has managed the establishment, development and profitable growth of the business since formation in 2006 to deliver key strategic elements of the business plan. Andy has nearly 25 years' experience in international business management, including both operational capability development and financial control, while supporting major commercial deal making. Prior to joining Prosonix, he was Operations Manager of the C3 Technology Business of Accentus and previously held senior positions in two AEA Technology businesses in change management and business transformation roles. Before that he enjoyed a highly successful 18-year career in BOC spanning technical, operations and commercial management and was responsible for winning several long-term, multi-million pound business contracts. Andy holds a Bachelors' Degree in Chemical Engineering and is a Chartered Engineer. He also holds a Masters' Degree in Business Administration.

Cécile has extensive business development and commercial experience within the pharmaceutical, biotechnology and generics sector, and strong global networks. She joins Prosonix from the Watson group (now known as Actavis, Inc.), the world's third-largest generics company, where she was Commercial Director EU. Before Watson, Cécile was Executive Director of Commercial Development at Ark Therapeutics, Executive Director of Global Business Development at Pliva, and Head of the European Division at Ranbaxy Laboratories Ltd. She also spent several years in a variety of commercial roles at Fisons plc.

Geoff has more than 18 years' clinical development experience in the pharmaceutical sector, following ten years in clinical practice in a range of hospital specialties. Before joining Prosonix in 2012, he successfully ran his own company providing services as a consultant pharmaceutical physician to Pfizer, RespiVert and most recently, GlaxoSmithKline's R&D Respiratory and Immuno-Inflammation medicines development centre (GSK RII MDC). He worked in a permanent role at GSK RII MDC from 2002 to 2007, as Director Clinical Pharmacology and Discovery Medicine. In this position, he managed global clinical development programmes and post-licensing support, making significant contributions to the progression of two significant programmes through to global marketing licence submissions [Ariflo (oral cilomilast for COPD) and Avamys/Veramyst (inhaled fluticasone furoate for allergic rhinitis]. He has also held senior roles at Johnson & Johnson Pharmaceutical R&D, ASTA Medica/Baxter and Rhône-Poulenc Rorer. Geoff has been a principal investigator or company sponsor for more than 50 early clinical development studies and over 30 full clinical development trials. He has authored and co-authored several papers, principally in the respiratory field. Geoff is a Fellow and Senior Specialist Adviser at the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians (UK).

Rob has over 20 years' experience in pharmaceutical regulatory affairs and drug development, with significant expertise in the area of generic respiratory and inhaled medicines. Since 1999, he has been Managing Director of PhRAction (formerly Pharmaxis), a pharmaceutical regulatory affairs and drug development consultancy, at which he was responsible for ten submissions of orally inhaled drug products to international regulatory agencies. Before that, Rob held senior drug development regulatory affairs positions at companies including Boehringer Ingelheim, Norton Healthcare (now Teva EU) and Glaxo Group Research (now GSK). Rob is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).

John holds two degrees in Mathematics and a PhD in Chemical Engineering. He worked for eight years at Newcastle University developing equipment in the field of Process Intensification, then moved on to work for three years at Protensive Ltd as Research and Development Manager. Whilst at Protensive, John was actively involved in the development of Spinning Disc Reactor technology. John joined Prosonix in 2006.

Ludovic holds a Chemical Engineering Diploma and a PhD in Catalysis and Synthetic Chemistry. He joined Prosonix in 2007 having previously worked with Bristol Myers Squibb and Evotec (now part of Aptuit) in Process Development and Custom Preparation.